Program
Oxycodone
Also written as “Reformulated OXY (oxycodone HCl)”, “Oxycodone/Naloxone” and “oxycodone hydrochloride”.
Its studies are mostly in Pain · Neoplasms · Osteoarthritis · Cancer Pain · Chronic Pain, led by 13 companies.
Drug pageOxycodone: every studyMany companies study it; this page follows only the 64 they lead. All 209 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mundipharmaits history only | 200 open or running | phase 4since Mar 8, 2011 | Jul 27, 2007 | none ahead |
| Knoa Pharmaits history only | 120 open or running | phase 3since Apr 6, 2006 | Apr 6, 2006 | none ahead |
| Pain Therapeutics | 120 open or running | phase 3since Mar 13, 2012 | Aug 12, 2008 | none ahead |
| Pfizerits history only | 60 open or running | phase 4since Jun 8, 2007 | Jun 8, 2007 | none ahead |
| Egaletits history only | 30 open or running | phase 3since Nov 10, 2015 | Dec 2, 2008 | none ahead |
| Keenova Therapeuticsits history only | 30 open or running | phase 1since Feb 26, 2009 | Feb 26, 2009 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| biodelivery-sciences-internationalits history only | 10 open or running | phase 1since Jun 21, 2019 | Jun 21, 2019 | none ahead |
| elite-laboratories-incits history only | 10 open or running | phase 3since Feb 17, 2015 | Feb 17, 2015 | none ahead |
| gl-pharm-tech-corporationits history only | 10 open or running | phase 1since Mar 19, 2012 | Mar 19, 2012 | none ahead |
| Indivior Pharmaceuticalsits history only | 10 open or running | phase 1since Nov 16, 2018 | Nov 16, 2018 | none ahead |
| napp-pharmaceuticals-limitedits history only | 10 open or running | phase 4since Nov 3, 2008 | Nov 3, 2008 | none ahead |
| vistapharm-incits history only | 10 open or running | phase 4since Jul 3, 2013 | Jul 3, 2013 | none ahead |
Also a collaborator on its studies: PRA Health Sciences and Grünenthal.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pain Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 12, 2008First study: phase 2 study in Opioid-Related DisordersFirst studyNCT00734461 · 14 enrolled · United States
- Mar 9, 20122 phase 1 studies in PainNCT01552863, NCT01552850
- Mar 13, 2012Phase 3 study in PainNCT01559701 · 823 enrolled
- Oct 26, 2012Phase 1 study in HealthyNCT01717027 · 19 enrolled · United States
- Aug 14, 2013Phase 1 study in HealthyNCT01924676 · 18 enrolled · United States
- Nov 1, 2013Phase 1 study in Substance-Related DisordersNCT01986283 · 67 enrolled · United States
- Feb 7, 2014Phase 1 study in HealthyNCT02059915 · 134 enrolled · United States
- Mar 13, 2014Phase 1 study in HealthyNCT02089295 · 18 enrolled · United States
- Apr 16, 2014Phase 1 study in HealthyNCT02117583 · 34 enrolled · United States
- Jun 10, 2014Phase 1 study in HealthyNCT02165930 · 17 enrolled · United States
- Mar 7, 2018Phase 1 study in Opioid Abuse NondependentNCT03475862 · 38 enrolled · United States
TargetBeta
“Mu opioid receptor agonist; Mu opioid receptor agonist; Mu opioid receptor agonist”ChEMBL 37, by rule
Other programs on OPRM1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 20 |
| Methadonerule | Merck | phase 4 | 16 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
| axelopranrule | glycyx-therapeutics | phase 2 | 8 |
| Alfentanilrule | Sichuan Kelun Pharmaceutical | phase 1 | 1 |
Studies
All 12 Pain Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03475862Opioid Abuse Nondependent · United States | 1 | Completed | Jul 31, 2017 | 38 |
| NCT02165930Healthy · United States | 1 | Completed | Aug 2014 | 17 |
| NCT02117583Healthy · United States | 1 | Completed | Aug 2014 | 34 |
| NCT02089295Healthy · United States | 1 | Completed | Jun 2014 | 18 |
| NCT02059915Healthy · United States | 1 | Completed | Jul 2014 | 134 |
| NCT01986283Substance-Related Disorders · United States | 1 | Completed | Aug 2014 | 67 |
| NCT01924676Healthy · United States | 1 | Completed | Oct 2013 | 18 |
| NCT01717027Healthy · United States | 1 | Completed | Jan 2013 | 19 |
| NCT01559701Pain | 3 | Completed | Feb 2008 | 823 |
| NCT01552863Pain · United States | 1 | Completed | Sep 2012 | 21 |
| NCT01552850Pain · Singapore | 1 | Completed | Jun 2012 | 18 |
| NCT00734461Opioid-Related Disorders · United States | 2 | Completed | Mar 2009 | 14 |
How it is read
Names in the registry
- “Oxycodone”, 43 entries
- “Reformulated OXY (oxycodone HCl)”, 6 entries
- “Oxycodone/Naloxone”, 5 entries
- “oxycodone hydrochloride”, 4 entries
- “Oxycodone hydrochloride”, 3 entries
Conditions, from the studies’ own filings
- Pain, 15 studies
- Neoplasms, 7 studies
- Osteoarthritis, 4 studies
- Cancer Pain, 3 studies
- Chronic Pain, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.